Ofichem Group has consolidated its multiple business units under a single brand identity, marking a strategic shift aimed at simplifying engagement with pharmaceutical and biotech partners.

Effective April 1, the company has unified its portfolio—including Ofichem BV, Ofipharma, Ofimedicine, Labatorium Ofichem, Ofichem Uppsala and Avivia—under the Ofichem name. The move brings together capabilities spanning active pharmaceutical ingredients (API), drug substance, drug product development, and sourcing and distribution into one integrated offering.

The consolidation comes as pharmaceutical companies increasingly seek to reduce operational complexity by working with fewer, more comprehensive partners capable of supporting the full drug development lifecycle. By presenting a unified structure, Ofichem aims to provide clients with a clearer view of its end-to-end capabilities while maintaining the same standards of quality, compliance and responsiveness.

Weite Oldenziel, CEO of Ofichem, said, “We have built strong expertise across API, drug substance, drug product and supply over time. Bringing all brands together under one identity allows us to better showcase how these capabilities connect, enabling us to support customers in a more consistent and integrated way.”

The company said the transition is focused on aligning teams, capabilities and communication, making it easier for customers to access its full range of services—from early-stage development to commercial-scale supply—through a single interface.

Importantly, Ofichem clarified that the rebranding will not affect its legal entities, existing contracts, services, quality systems or customer relationships. Clients will continue to work with the same teams, ensuring continuity alongside improved visibility of the organisation’s offerings.

The move also strengthens Ofichem’s position as a Europe-based contract development and manufacturing organisation (CDMO), at a time when the industry is placing increased emphasis on supply chain security, transparency and regional reliability.

With more than 50 years of regulatory expertise and GMP-certified operations, Ofichem continues to position itself as a flexible and responsive partner for pharmaceutical and compounding companies, supporting projects from small-scale batches to large commercial supply.